CompletedPhase 2

Protocol for Women at Increased Risk of Developing Breast Cancer

United States42 participantsStarted 2003-01

Plain-language summary

A pilot study to assess the effects of six months of letrozole on breast tissue risk markers in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast * on hormone replacement therapy * postmenopausal * increased risk of developing breast cancer based on personal or family history * never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months * women who have a high risk of breast cancer * older than 18 years Exclusion Criteria: * anticoagulants * marked breast tenderness * pregnant or within twelve months of breast feeding/childbirth

What they're measuring

Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration.

Timeframe: Baseline, 6 months

Trial details

NCT IDNCT00291135

SponsorCarol Fabian, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-10

Results submitted2013-06-24

View on ClinicalTrials.gov More Breast Cancer trials